- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04515121
High-definition Transcranial Electrical Stimulation for Lower Limb Stroke Rehabilitation
January 28, 2023 updated by: Lai chien hung, Taipei Medical University Hospital
Effects of High-definition Transcranial Electrical Stimulation on the Lower Extremity in Patients With Stroke
Transcranial electrical stimulation (tCES) is a non-invasive and safe treatment, which uses a low direct current or alternating current to change the excitability of the cerebral cortex.
The tCES has been applied in clinical trials related to rehabilitation research in recent years, and the safety and effectiveness have also been established.
However, the existing tCES products effect on the whole brain networks and lack special waveforms.
We developed a wearable high-definition tCES (HD-tCES) with special waveforms.
This novel stimulation system will result in more precise and focal stimulation of selected brain regions with special waveforms to display better neuromodulation performance.
In this study, we will preliminarily examine the effects and safety of the HD-tCES on lower extremity in patients with stroke.
We expect that the HD-tCES combined with the lower extremity rehabilitation can shorten the duration of rehabilitative periods, improve stroke patients' activity of daily living, reduce the care burden of patients' family, and subsequently decrease the cost of health care insurance.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chien-Hung Lai, PhD
- Phone Number: 1236 +886-2-27372181
- Email: chlai@tmu.edu.tw
Study Locations
-
-
-
New Taipei City, Taiwan, 235
- Recruiting
- Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare
-
Contact:
- Hung-Chou Chen, MD
- Phone Number: +886-970-747-158
- Email: b8601084@tmu.edu.tw
-
Sub-Investigator:
- Hung-Chou Chen, MD
-
Sub-Investigator:
- Shih-Wei Huang, PhD
-
Taipei, Taiwan, 110
- Recruiting
- Taipei Medical University Hospital
-
Contact:
- Chien-Hung Lai, PhD
- Phone Number: 1236 +886-2-27372181
- Email: chlai@tmu.edu.tw
-
Principal Investigator:
- Chien-Hung Lai, PhD
-
Taipei, Taiwan, 116
- Recruiting
- Taipei Municipal Wanfang Hospital - Taipei Medical University
-
Contact:
- Kwang-Hwa Chang, MS
- Phone Number: +886-970-746-881
- Email: chang2773@gmail.com
-
Sub-Investigator:
- Kwang-Hwa Chang, MS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- With a diagnosis of stroke.
- Age ≥ 20 years.
- Hemiplegia, Brunnstrom stage III-V.
- 6 months to 5 years after stroke.
- Muscular inelasticity (spasticity) 1-3 on the affected lower limb, evaluated by the Modified Ashworth Scale.
- Ability to walk for 10 min non-stop with no gait aids or ability to walk 20 m with supervision or slight assistance.
Exclusion Criteria:
- Intolerance to electrical stimulation.
- Contracture on lower extremities, and limitation in joint range of motion.
- Severe spasticity.
- Ossification or inflammation in muscle tissue.
- A history of arrhythmia.
- Implantable medical electronic devices (e.g., like pacemaker).
- Metal implants in the head or neck.
- Wounds on the skin of head.
- A history of brain surgery or severe brain trauma.
- Severe cognitive or psychiatric disorders (e.g., schizophrenia, depression or bipolar disorder).
- A history of seizure or other brain pathology.
- Drug or alcohol abuse.
- Malignant neoplasm or rheumatism disorder (e.g., SLE, RA, AS, IBD)
- Undergoing other non-invasive brain stimulation.
- Intra-cerebral lesions (such as brain tumors, arteriovenous tumors).
- History of encephalitis or meningitis.
- Stroke lesion in cerebellum or brainstem.
- Leg amputation.
- Sleep deprivation.
- Severe or recent heart disease.
- Subjects who use drugs that may lower the seizure threshold.
- Pregnant or breastfeeding women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HD-tCES & lower limb rehabilitation
The experiment group will receive HD-tCES combined with lower limb rehabilitation of affected side.
|
The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration.
The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere).
HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living.
Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
|
SHAM_COMPARATOR: Sham HD-tCES & lower limb rehabilitation
The sham control group will receive sham HD-tCES combined with lower limb rehabilitation of affected side.
|
Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living.
Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration.
The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere).
Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the Fugl-Meyer Assessment lower extremity scale (FMA-LE) after intervention
Time Frame: Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
The FMA-LE assesses motor functioning of lower extremity.
Each movement is estimated by a 3-point scale (0-1-2).
The total score of the FMA-LE is 34, and a higher score indicates that the patient has better movement ability.
|
Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the Berg Balance Scale (BBS) after intervention
Time Frame: Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
The BBS is used to objectively determine a patient's ability to safely balance during a series of predetermined tasks.
It contains 14 items with each item consisting of a five-point ordinal scale ranging from 0 to 4. A higher score indicates that the patient has better balance.
|
Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
Change from baseline in the Timed Up and Go Test (TUG) after intervention
Time Frame: Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
The TUG assesses a patient's mobility and requires both static and dynamic balance.
It measures the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
|
Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
Change from baseline in the Gait Evaluation after intervention
Time Frame: Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
The Gait Evaluation includes cadence, stride duration, stride length, and velocity.
|
Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
Change from baseline in the Modified Ashworth Scale (MAS) after intervention
Time Frame: Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
The MAS is commonly used in clinical practice for grading spasticity.
The MAS is rated on a 6-point scale (0, 1, 1+, 2, 3, 4), and a higher score indicates that the patient has higher muscle tension.
The muscles being assessed include hip flexor, hip extensor, knee flexor, knee extensor, ankle dorsiflexor, and ankle plantarflexor.
|
Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
Change from baseline motor evoked potential (MEP) after intervention
Time Frame: Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
The MEP elicited in peripheral muscles by transcranial magnetic stimulation over motor cortex is one of the hallmark measures for non-invasive quantification of cortical excitability.
|
Baseline (within 7 days ahead to the 1st intervention session) and after 4-week intervention (within 7 days after the last intervention session)
|
Incidence of treatment-emergent adverse events
Time Frame: Within 10 minutes after each intervention session (a total of 12 sessions, 3 sessions/week, lasting 4 weeks)
|
Immediately after each HD-tCES stimulation, the patient will be questioned about eventual side effect.
|
Within 10 minutes after each intervention session (a total of 12 sessions, 3 sessions/week, lasting 4 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 20, 2020
Primary Completion (ANTICIPATED)
October 31, 2023
Study Completion (ANTICIPATED)
December 31, 2023
Study Registration Dates
First Submitted
August 13, 2020
First Submitted That Met QC Criteria
August 13, 2020
First Posted (ACTUAL)
August 17, 2020
Study Record Updates
Last Update Posted (ACTUAL)
January 31, 2023
Last Update Submitted That Met QC Criteria
January 28, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- N202004091
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on HD-tCES
-
Taipei Medical UniversityNational Cheng Kung University; Ministry of Science and Technology, R.O.C (Taiwan)Completed
-
Taipei Medical UniversityMinistry of Health and WelfareCompleted
-
Taipei Medical UniversityMinistry of Science and Technology, TaiwanCompleted
-
Okuvision GmbHCompleted
-
Okuvision GmbHCompletedRetinitis PigmentosaNorway, Denmark, Germany
-
Okuvision GmbHCONET GmbH - Clinical Operations NetworkCompleted
-
University of LouisvilleWithdrawnSpinal Cord InjuriesUnited States
-
University Hospital, BordeauxCompleted
-
University of CalgaryCompletedInflammatory Bowel DiseaseCanada
-
Ariel UniversityTel Aviv UniversityCompleted